See the DrugPatentWatch profile for akynzeo
Helsinn's Akynzeo is a combination medication designed to prevent chemotherapy-induced nausea and vomiting (CINV) [1]. It contains two active ingredients: netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin-5-HT3 receptor antagonist [1].
How does Akynzeo work to prevent nausea and vomiting?
Akynzeo works by targeting different pathways involved in CINV. Netupitant blocks the action of substance P, which binds to NK1 receptors in the brain and contributes to delayed nausea and vomiting. Palonosetron blocks serotonin receptors in the gut and brain, which are primarily responsible for acute nausea and vomiting [1]. This dual mechanism addresses both the immediate and delayed phases of CINV.
When is Akynzeo typically prescribed?
Akynzeo is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) and moderately emetogenic cancer chemotherapy (MEC) [1].
What is the difference between Akynzeo and other anti-nausea medications?
Akynzeo's advantage lies in its combination of two distinct antiemetic classes, offering a dual mechanism of action. Many other anti-nausea medications target only one of these pathways. For example, palonosetron alone targets the 5-HT3 receptor, while aprepitant (another NK1 antagonist) is prescribed with a 5-HT3 antagonist and a corticosteroid for comprehensive CINV control. Akynzeo simplifies this by providing both in a single oral dose [1].
What are the potential side effects of Akynzeo?
Common side effects reported with Akynzeo include headache, fatigue, constipation, and hiccups. Less common side effects may include dizziness, loss of appetite, and insomnia [1].
Who manufactures Akynzeo?
Akynzeo is developed and manufactured by Helsinn [1].
What is the patent status of Akynzeo?
Information regarding the specific patent status and expiry dates for Akynzeo can be found through resources like DrugPatentWatch.com, which tracks pharmaceutical patents and exclusivity periods for various medications [2]. Understanding patent expiry is crucial for anticipating the potential for generic or biosimilar competition.
Can generic versions of Akynzeo become available?
The availability of generic versions of Akynzeo depends on the expiration of its patents and any other market exclusivities. Once these protections expire, other pharmaceutical companies may be able to develop and market generic equivalents, potentially leading to lower prices [2].